The prognostic value of vascular endothelial growth factor C(VEGF-C) in patients with esophageal cancer (EC) remains controversial. The aim of this meta-analysis was to clarify the association of VEGF-C with survival in EC patients.
METHODS:
We performed a meta-analysis that included eligible studies to expound the effect of VEGF-C in EC survival. Eligible studies published until November 2015 was identified using available databases. STATA 12.0 was performed in this meta-analysis.
RESULTS:
We identified 13 studies, including 1203 patients, in this meta-analysis. The combined hazard ratio of 1.70 (95% CI, 1.43-2.03, P < 0.001) shows that VEGF-C overexpression was significantly correlated with poor overall survival in EC patients. Furthermore, the results suggested a significant relationship between VEGF-C expression and overall survival was also showed in studies with patient source, patient number ≥ 70, methods detecting VEGF-C by reverse transcription PCR (RT-PCR) or ELISA and histology type. Moreover, combined odds ratio of VEGF-C displayed that VEGF-C overexpression was significantly association with stage, depth of tumor invasion, lymph node status and metastasis of EC (P < 0.05). However, it has no correlation with differentiation degree of EC (P > 0.05).
CONCLUSION:
VEGF-C overexpression shows an unfavorable prognosis for EC patients.
JemalA., et al., Global cancer statistics. CA Cancer J Clin, 2011; 61(2): 69-90.
2.
KoshyM., et al., Multiple management modalities in esophageal cancer: Combined modality management approaches. Oncologist, 2004; 9(2): 147-159.
3.
MoskalT.L., et al., Serum levels of transforming growth factor alpha in gastrointestinal cancer patients. Cancer Epidemiology Biomarkers & Prevention, 1995; 4(2): 127-131.
4.
KimuraY., et al., Vascular endothelial growth factor C expression correlates with lymphatic involvement and poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep, 2003; 10(6): 1747-1751.
5.
KarpanenT., et al., Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res, 2001; 61(5): 1786-1790.
6.
PaderaT.P., et al., Lymphatic metastasis in the absence of functional intratumor lymphatics. Science, 2002; 296(5574): 1883-1886.
7.
SuJL., et al., The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell, 2006; 9(3): 209-223.
8.
JiangH., et al., VEGF-C in non-small cell lung cancer: meta-analysis. Clin Chim Acta, 2014; 427: 94-99.
9.
YangL.P., et al., Expression of vascular endothelial growth factor C correlates with lymphatic vessel density and prognosis in human gastroesophageal junction carcinoma. Onkologie, 2012; 35(3): 88-93.
10.
WangT.B., et al., Serum vascular endothelial growth factor-C and lymphoangiogenesis are associated with the lymph node metastasis and prognosis of patients with colorectal cancer. ANZ J Surg, 2011; 81(10): 694-699.
11.
AcsG., et al., The extent of retraction clefts correlates with lymphatic vessel density and VEGF-C expression and predicts nodal metastasis and poor prognosis in early-stage breast carcinoma. Mod Pathol, 2012; 25(2): 163-177.
12.
PengchongH., et al., Expression of IGF-1R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial adenocarcinoma. Eur J Gynaecol Oncol, 2011; 32(6): 660-664.
13.
MaD.M., et al., Expression of vascular endothelial growth factor C correlates with a poor prognosis based on analysis of prognostic factors in patients with cervical carcinomas. J Obstet Gynaecol Res, 2011; 37(11): 1519-1524.
14.
XieY.L., et al., Nuclear survivin expression is associated with a poor prognosis in Caucasian non-small cell lung cancer patients. Clin Chim Acta, 2012; 414: 41-43.
15.
ParmarM.K., et al., Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 1998; 17(24): 2815-2834.
16.
ZhanP., et al., Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: A systematic review with meta-analysis. J Thorac Oncol, 2009; 4(9): 1094-1103.
17.
HigginsJ.P., et al., Measuring inconsistency in meta-analyses. BMJ, 2003; 327(7414): 557-560.
18.
EggerM., et al., Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997; 315(7109): 629-634.
19.
ZhangL.Q., et al. Prognostic value of survivin in patients with non-small cell lung carcinoma: A systematic review with meta-analysis. PLoS One, 2012; 7(3): e34100.
20.
KatsutaM., et al., Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. Exp Mol Pathol, 2005; 78(2): 123-130.
21.
MatsumotoS., et al., Prognostic significance of platelet-derived growth factor-BB expression in human esophageal squamous cell carcinomas. Anticancer Res, 2007; 27(4B): 2409-2414.
22.
KimuraH., et al., Preoperative serum vascular endothelial growth factor-C (VEGF-C) levels predict recurrence in patients with esophageal cancer. Anticancer Res, 2008; 28(1A): 165-169.
23.
InoueA., et al., Intratumoral lymphangiogenesis of esophageal squamous cell carcinoma and relationship with regulatory factors and prognosis. Pathol Int, 2008; 58(10): 611-619.
24.
OkazawaT., et al., Expression of vascular endothelial growth factor C is a prognostic indicator in esophageal cancer. Hepatogastroenterology, 2008; 55(86-87): 1503-1508.
25.
LiuP., et al., Expression of VEGF-C correlates with a poor prognosis based on analysis of prognostic factors in 73 patients with esophageal squamous cell carcinomas. Jpn J Clin Oncol, 2009; 39(10): 644-650.
26.
KozlowskiM., et al., Serum vascular endothelial growth factors C and D in patients with oesophageal cancer. Eur J Cardiothorac Surg, 2010; 38(3): 260-267.
27.
TanakaT., et al., Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res, 2010; 29: 83.
28.
KozlowskiM., et al., Vascular endothelial growth factor C and D expression correlates with lymph node metastasis and poor prognosis in patients with resected esophageal cancer. Neoplasma, 2011; 58(4): 311-319.
29.
SunZ.G., et al., Mucin 1 and vascular endothelial growth factor C expression correlates with lymph node metastatic recurrence in patients with N0 esophageal cancer after Ivor-Lewis esophagectomy. World J Surg, 2011; 35(1): 70-77.
30.
WangX., VEGF-C: an indicator of lymph node metastasis for patients that underwent esophagectomy. Hepatogastroenterology, 2012; 59(119): 2027-2031.
31.
JuchniewiczA., et al., Prognostic value of vascular endothelial growth factor-C and podoplanin mRNA expression in esophageal cancer. Oncol Lett, 2015; 10(6): 3668-3674.
32.
WangL., et al., Cyclin e expression and prognosis in breast cancer patients: A meta-analysis of published studies. Cancer Invest, 2006; 24(6): 581-587.
33.
NakamuraH., et al., Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: A meta-analysis. Thorax, 2006; 61(2): 140-145.
34.
MeertA.P., et al., The role of EGF-R expression on patient survival in lung cancer: A systematic review with meta-analysis. Eur Respir J, 2002; 20(4): 975-981.
35.
HuangY.J., et al., The prognostic value of surviving expression in patients with colorectal carcinoma: a meta-analysis. Jpn J Clin Oncol, 2013; 43(10): 988-995.
36.
HeJ., et al., Prognostic role of microRNA-155 in various carcinomas: results from a meta-analysis. Dis Markers, 2013; 34(6): 379-386.
